Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries

Stemedica Cell Technologies, Inc., a world leader in stem cell research and
manufacturing (a licensed manufacturer of clinical grade biological products
as licensed by the State of California Food and Drug Branch) continues to
advance the stem cell industry with the presentation of two of its latest
scientific discoveries at the 2009 World Stem Cell Summit

SAN DIEGO, Aug. 27 /PRNewswire/ -- Stemedica Cell Technologies , Inc.,
("Stemedica"), a world leader in stem cell research and manufacturing (a
licensed manufacturer of clinical grade biological products as licensed by the
State of California Food and Drug Branch) continues to advance the stem cell
industry with the presentation of two of its latest scientific discoveries at
the 2009 World Stem Cell Summit. "We are honored to have the work of our
scientific research team selected for presentation at this year's Summit.
This work is expected to increase the efficacy and significantly reduce the
time and cost in bringing important research from the bench top to clinical
application," said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief
Medical Officer.

The first discovery accepted by the Summit's Peer Review Committee was
submitted by Chih-Min Lin, PhD, a Stemedica Senior Research Scientist. His
submittal is entitled, "Chicken Embryonic Brain: A Model for Testing Neural
Stem Cell Potency." This Neural Stem Cell Evaluation Model determines the
potency of neural stem cells and quickly assesses their ability to migrate and
engraft inside the developing brain. Stemedica's technology allows neural
precursors to be distinguished at various stages of their maturation,
providing timely and cost effective verification of neural stem cell potency
in vivo.

"The currently used process for assessing the in vivo potency of neural stem
cells in newborn mice is extremely time consuming and expensive. This
traditional process also involves the use and sacrifice of animals in
facilities separate from manufacturing. Stemedica's discovery and patent
pending technology eliminates the need for animals and replaces this arduous
process with a significantly more effective and efficacious model. This model
can be deployed within laboratory environment and the evaluation results can
be attained in less than two weeks instead of the two to four months using
traditional animal testing models," said Alex Kharazi, MD, PhD, Stemedica's
Vice President of Research and Manufacturing.

The second finding accepted for presentation at the 2009 World Stem Cell
Summit was submitted by Ludmila Kharazi, MD, PhD, Stemedica's Senior Research
Scientist. Her submittal is entitled, "Up-Regulation of Wound Healing
Associated Proteins in Long-Term Culture of Human Keratinocyte Precursor
Cells." Dr. Kharazi's work demonstrates that long term cultivation of human
keratinocytes in serum free, low-Ca++ media (SFM) leads to the increased
expression of genes for wound healing-associated proteins such as fibronectin,
metalloproteinase (MMP9, MMP10), and tissue-type plasminogen activator (TPA).
The purpose of Dr. Kharazi's work was to determine how the propagation of
human skin keratinocyte precursor cells (KPC) in SFM to clinically significant
numbers will affect their ability to produce fibronectin and other wound
healing associated proteins.

"Current technology for the treatment of burns, chronic wounds and diabetic
ulcers is extremely expensive, time consuming and lacking in efficacy. Dr.
Ludmila Kharazi's finding suggests that using long term cultivated
keratinocyte precursor cells may result in reducing the time of healing while
lowering the overall treatment cost. As Stemedica continues to make great
advancements in products that can treat burns, chronic wounds and diabetic
ulcers, Dr. Ludmila Kharazi's work is pivotal in providing the Company with
advancements that will make our products, and ultimately patient treatment
results, the best the industry has to offer," said Dr. Tankovich. This finding
compliments Stemedica's existing proprietary burn and wound care product
currently in clinical trials in Switzerland.

The 2009 World Stem Cell Summit is being held in Baltimore, Maryland from
September 21st - 23rd. Presented by the Genetics Policy Institute, the 2009
Summit is hosted by Johns Hopkins University and other leadership
organizations from within the stem cell industry, bringing together more than
1,200 researchers, clinicians, business leaders, key policy makers,
regulators, advocates, and experts in law & ethics from around the world.

Licensing of the Stemedica's Neural Stem Cell Evaluation Model Intellectual
Property is available to a select number of companies. Additionally,
Stemedica is prepared to accept a limited number of projects where the
Company's scientific team conducts the neural stem cell potency evaluation.

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty
biopharmaceutical company that is committed to the development and
manufacturing of best-in-class adult stem cells and stem cell factors for use
by approved research institutions and hospitals for pre-clinical and human
clinical trials. The company is currently developing regulatory pathways for
stroke and wound repair. Stemedica is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave
McGuigan at dmcguigan (at)stemedica.com.

SOURCE Stemedica Cell Technologies, Inc.

Dave McGuigan of Stemedica Cell Technologies Inc., +1-949-387-4862, dmcguigan
(at)stemedica.com